Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of biosimilar to Humira

Boehringer Ingelheim has announced results from the pivotal Phase III VOLTAIRE®-RA(1) study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.

Bron: World Pharma News Meer lezen »

Weakness discovered in malaria parasite could lead to new treatment

A protein has been newly discovered that could lead to an alternative form of vaccination against the spread of malaria parasites. The protein, named PfAP2-I, allows the malaria parasite to invade red blood cells, where it is then able to multiply and spread.

Bron: Pharmafile Meer lezen »

From pipeline to patients: Navigating treatments through the UK system

Pharmafocus spoke to Karen Lightning-Jones, Integrated Franchise Leader, Pipeline, to discuss the current UK climate for successfully developing drugs to provide to patients, covering what is needed by the next government and how Switzerland provides a model to thrive outside the EU.

Bron: Pharmafile Meer lezen »

Antibiotics Tied to Side Effects in Nearly 20% of Hospitalized Patients, Says Study

Researchers from The Johns Hopkins Hospital found that nearly 1 in 5 hospitalized adults developed an antibiotic-associated adverse drug event after receiving antibiotic therapy. Findings from their study are published in JAMA Internal Medicine. The team evaluated electronic medical records of 1,488 adult patients admitted to Johns Hopkins Hospital between September 2013–June 2014 who received at least 24 hours of oral or parenteral antibiotic therapy.

Bron: Monthly Prescribing Reference (MPR): Drug News Meer lezen »

Will AstraZeneca’s SGLT2-favoring data win the class a shot at front-line diabetes use?

Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest.

Bron: FiercePharma Meer lezen »

Animaties tonen verspreiding nieuwe medicijnen

Animaties zijn een goede manier om inzicht te krijgen in de verspreiding van nieuwe geneesmiddelen. Dit kan beleidsmakers helpen gerichte actie te ondernemen. Onder leiding van het Instituut voor Verantwoord Medicijngebruik (IVM) zijn in het pilotproject MOVIE animaties gemaakt voor nieuwe antistollingsmiddelen en nieuwe geneesmiddelen tegen diabetes.

Bron: Medicalfacts Meer lezen »

FDA to review effectiveness of abuse deterrent opioid drugs

FDA Commissioner Scott Gottlieb continues his fightback against the US opioid crisis after requesting an unprecedented recall of Endo Pharmaceuticals’ painkiller Opana ER by calling for a review of all ‘abuse deterrent’ opioid drugs to confirm their efficacy at preventing addiction and abuse.

Bron: Pharmafile Meer lezen »

SEA-ontwikkelingen & trends in 2017: laat je even bijpraten

Online gevonden worden. Dit is nog steeds één van de belangrijkste punten op de to-dolijst van menig ondernemer. Maar hoe zorg je daarvoor? Wij hebben een aantal van onze zoekmachinemarketing-specialisten aan hun jasje getrokken om je bij te praten. De 7 trends voor search engine advertising in 2017 hebben we op een rijtje gezet.

Bron: marketingfacts.nl Meer lezen »

Type 1 Diabetes Reversal May be Possible with TB Vaccine

Faustman’s team is preparing for a 5-year, 150-person Phase 2 trial to investigate the potential for repeat BCG vaccination to improve type 1 diabetes in adults with existing disease. According to data from a recent Phase 1 trial directed by the Massachusetts General Hospital Immunobiology Laboratory, the vaccine bacillus Calmette-Guérin (BCG) may have the potential to reverse type 1 diabetes.

Bron: Monthly Prescribing Reference (MPR): Drug News Meer lezen »

Bayer, J&J win second U.S. trial over Xarelto bleeding risks

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday.

Bron: Reuters Meer lezen »